title: The effect of nasal hCT on bone turnover in Paget's disease of bone--implications for the treatment of other metabolic bone diseases.
abstract: Thirty pagetic patients were treated for 6 months with a daily nasal application of 2 mg of synthetic human calcitonin (hCT). Serum alkaline phosphatases (SAP) and urinary hydroxyproline/creatinine ratio (OH/Cr), reflecting bone turnover, were significantly reduced from the first month of treatment (mean +/- SEM: SAP, -13.9 +/- 2.2%; OH/Cr, -22.2 +/- 5.8%; both P less than 0.01) and until the end of the 6-month course (mean +/- SEM: SAP, -29.7 +/- 4.6%; OH/Cr, -22.5 +/- 5.9%; both P less than 0.01). Nasal hCT was perfectly tolerated both locally and systemically. These results allow us to consider nasal hCT for long-term trials in metabolic bone diseases characterized by a relative increase of bone resorption.
authors.affiliation: Department of Rheumatology and Endocrinology, University of Liège, Belgium.
authors.forename: J Y
authors.initials: JY
authors.lastname: Reginster
authors.forename: A M
authors.initials: AM
authors.lastname: Jeugmans-Huynen
authors.forename: M
authors.initials: M
authors.lastname: Wouters
authors.forename: N
authors.initials: N
authors.lastname: Sarlet
authors.forename: H D
authors.initials: HD
authors.lastname: McIntyre
authors.forename: P
authors.initials: P
authors.lastname: Franchimont
mesh_terms: D000281:Administration, Intranasal; D000368:Aged; D000369:Aged, 80 and over; D000469:Alkaline Phosphatase / Q000097:blood; D001851:Bone Diseases, Metabolic / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D002116:Calcitonin / Q000008:administration & dosage* / Q000627:therapeutic use; D003404:Creatinine / Q000652:urine; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D008297:Male; D008875:Middle Aged; D010001:Osteitis Deformans / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D002116:Calcitonin; D003404:Creatinine; D000469:Alkaline Phosphatase; D006909:Hydroxyproline